These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 31145074

  • 1. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N, Blakeway E, Mitra A.
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract] [Full Text] [Related]

  • 2. PD-1 inhibitor induced alopecia areata.
    Guidry J, Brown M, Medina T.
    Dermatol Online J; 2018 Dec 15; 24(12):. PubMed ID: 30677804
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T, Szlosarek PW, Shamash J, Rashid S.
    Eur J Cancer; 2018 Oct 15; 102():49-51. PubMed ID: 30138772
    [No Abstract] [Full Text] [Related]

  • 6. Remote-onset alopecia areata attributed to ipilimumab.
    Pearson DR, Lewis K, Alkousakis T.
    Cutis; 2019 Dec 15; 104(6):E25-E27. PubMed ID: 31939941
    [Abstract] [Full Text] [Related]

  • 7. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE, Loochtan AI, Bedlack RS.
    Muscle Nerve; 2018 Apr 15; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract] [Full Text] [Related]

  • 8. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K, McGettigan S, Elenitsas R, Chu EY.
    J Cutan Pathol; 2018 Jan 15; 45(1):74-77. PubMed ID: 29028121
    [Abstract] [Full Text] [Related]

  • 9. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N, Uchi H, Furue M.
    J Dermatol; 2017 Oct 15; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract] [Full Text] [Related]

  • 10. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
    Donaldson M, Owen JL, Choi JN.
    JAMA Dermatol; 2018 Jul 01; 154(7):846-847. PubMed ID: 29800007
    [No Abstract] [Full Text] [Related]

  • 11. [Treating metastatic melanoma: Risk management].
    Lebbe C, Robert C.
    Ann Dermatol Venereol; 2017 Jan 01; 144(1):3-5. PubMed ID: 28063593
    [No Abstract] [Full Text] [Related]

  • 12. Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment.
    Acaba-Berrocal LA, Lucio-Alvarez JA, Mashayekhi A, Ho AC, Dunn JP, Shields CL.
    JAMA Ophthalmol; 2018 Oct 01; 136(10):1205-1207. PubMed ID: 30054605
    [No Abstract] [Full Text] [Related]

  • 13. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K, Nakamura Y, Fujisawa Y, Endo R, Tanaka R, Ishitsuka Y, Maruyama H, Watanabe R, Okiyama N, Fujimoto M.
    Eur J Dermatol; 2018 Feb 01; 28(1):129-130. PubMed ID: 29400284
    [No Abstract] [Full Text] [Related]

  • 14. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A, Montaudie H, Bory P, Belgodere X, Passeron T, Lacour JP, Picard A.
    JAMA Dermatol; 2018 Nov 01; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract] [Full Text] [Related]

  • 15. A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma.
    Igari S, Yamamoto M, Kikuchi N, Ohtsuka M, Yamamoto T.
    An Bras Dermatol; 2024 Nov 01; 99(3):450-451. PubMed ID: 38307808
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
    Jespersen H, Bjursten S, Ny L, Levin M.
    Lancet Oncol; 2018 Jun 01; 19(6):e327. PubMed ID: 29893264
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hypothyroid ataxia complicating monoclonal antibody therapy.
    Badran A, Moran C, Coles AJ.
    Pract Neurol; 2017 Dec 01; 17(6):482-484. PubMed ID: 28778931
    [Abstract] [Full Text] [Related]

  • 20. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
    Prescrire Int; 2017 May 01; 26(182):118-119. PubMed ID: 30730667
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.